UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)

(Amendment No.  1) 1

Vical Incorporated	
 (Name of Issuer)	

Common Stock, $0.01 par value	
 (Title of Class of Securities)	

925602203	
 (CUSIP Number)	

December 31, 2018	
  (Date of Event Which Requires Filing of this Statement)	

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 	  ☐	 Rule 13d-1(b)	

 	  ☒	 Rule 13d-1(c)	

 	  ☐	 Rule 13d-1(d)	

 
1               The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ).

CUSIP No. 925602203

 	1	 	NAME OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	Biotechnology Value Fund, L.P.	 	
 	2	 	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ☒	
 	 	 	 	(b) ☐	
 	 	 	 	 	 	
 	3	 	SEC USE ONLY	 	 	

 	4	 	CITIZENSHIP OR PLACE OF ORGANIZATION	 	
 	 	 	 	 	
 	 	 	 	Delaware	 	
NUMBER OF	 	5	 	SOLE VOTING POWER	 	
SHARES	 	 	 	 	 	
BENEFICIALLY	 	 	 	 	0 shares	 	
OWNED BY	 	6	 	SHARED VOTING POWER	 	
EACH	 	 	 	 	 	
REPORTING	 	 	 	 	1,336,100 (1)	 	
PERSON WITH	 	7	 	SOLE DISPOSITIVE POWER	 	
	 	 	 	 	 	
 	 	 	 	 	0 shares	 	
 	 	8	 	SHARED DISPOSITIVE POWER	 	
 	 	 	 	 	 	
 	 	 	 	 	1,336,100 (1)	 	
 	9	 	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	1,336,100 (1)	 	
 	10	 	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	    ☐	

 	11	 	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	 	
 	 	 	 	 	
 	 	 	 	5.9% (1)	 	
 	12	 	TYPE OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	PN	 	
  
(1) Includes 992,750 shares of Common Stock currently issuable upon the exercise of the Warrants (as defined herein). Excludes 2,598,039 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation (as defined herein), which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

2 	
CUSIP No. 925602203

																				
 	1	 	NAME OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	Biotechnology Value Fund II, L.P.	 	
 	2	 	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ☒	
 	 	 	 	(b) ☐	
 	 	 	 	 	 	
 	3	 	SEC USE ONLY	 	 	

 	4	 	CITIZENSHIP OR PLACE OF ORGANIZATION	 	
 	 	 	 	 	
 	 	 	 	Delaware	 	
NUMBER OF	 	5	 	SOLE VOTING POWER	 	
SHARES	 	 	 	 	 	
BENEFICIALLY	 	 	 	 	0 shares	 	
OWNED BY	 	6	 	SHARED VOTING POWER	 	
EACH	 	 	 	 	 	
REPORTING	 	 	 	 	795,623 (1)	 	
PERSON WITH	 	7	 	SOLE DISPOSITIVE POWER	 	
	 	 	 	 	 	
 	 	 	 	 	0 shares	 	
 	 	8	 	SHARED DISPOSITIVE POWER	 	
 	 	 	 	 	 	
 	 	 	 	 	795,623 (1)	 	
 	9	 	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	795,623 (1)	 	
 	10	 	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	    ☐	

 	11	 	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	 	
 	 	 	 	 	
 	 	 	 	3.7% (1)	 	
 	12	 	TYPE OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	PN	 	
  
(1) Excludes 2,296,089 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock .

3 	
CUSIP No. 925602203

 	1	 	NAME OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	Biotechnology Value Trading Fund OS LP	 	
 	2	 	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ☒	
 	 	 	 	(b) ☐	
 	 	 	 	 	 	
 	3	 	SEC USE ONLY	 	 	

 	4	 	CITIZENSHIP OR PLACE OF ORGANIZATION	 	
 	 	 	 	 	
 	 	 	 	Cayman Islands	 	
NUMBER OF	 	5	 	SOLE VOTING POWER	 	
SHARES	 	 	 	 	 	
BENEFICIALLY	 	 	 	 	0 shares	 	
OWNED BY	 	6	 	SHARED VOTING POWER	 	
EACH	 	 	 	 	 	
REPORTING	 	 	 	 	106,239 (1)	 	
PERSON WITH	 	7	 	SOLE DISPOSITIVE POWER	 	
	 	 	 	 	 	
 	 	 	 	 	0 shares	 	
 	 	8	 	SHARED DISPOSITIVE POWER	 	
 	 	 	 	 	 	
 	 	 	 	 	106,239 (1)	 	
 	9	 	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	106,239 (1)	 	
 	10	 	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	    ☐	

 	11	 	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	 	
 	 	 	 	 	
 	 	 	 	Less than 1% (1)	 	
 	12	 	TYPE OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	PN	 	
  
(1) Excludes 615,779 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

4 	
CUSIP No. 925602203

 	1	 	NAME OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	BVF Partners OS Ltd.	 	
 	2	 	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ☒	
 	 	 	 	(b) ☐	
 	 	 	 	 	 	
 	3	 	SEC USE ONLY	 	 	

 	4	 	CITIZENSHIP OR PLACE OF ORGANIZATION	 	
 	 	 	 	 	
 	 	 	 	Cayman Islands	 	
NUMBER OF	 	5	 	SOLE VOTING POWER	 	
SHARES	 	 	 	 	 	
BENEFICIALLY	 	 	 	 	0 shares	 	
OWNED BY	 	6	 	SHARED VOTING POWER	 	
EACH	 	 	 	 	 	
REPORTING	 	 	 	 	106,239 (1)	 	
PERSON WITH	 	7	 	SOLE DISPOSITIVE POWER	 	
	 	 	 	 	 	
 	 	 	 	 	0 shares	 	
 	 	8	 	SHARED DISPOSITIVE POWER	 	
 	 	 	 	 	 	
 	 	 	 	 	106,239 (1)	 	
 	9	 	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	106,239 (1)	 	
 	10	 	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	    ☐	

 	11	 	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	 	
 	 	 	 	 	
 	 	 	 	Less than 1% (1)	 	
 	12	 	TYPE OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	CO	 	

(1) Excludes 615,779 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

5 	
CUSIP No. 925602203

 	1	 	NAME OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	BVF Partners L.P.	 	
 	2	 	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ☒	
 	 	 	 	(b) ☐	
 	 	 	 	 	 	
 	3	 	SEC USE ONLY	 	 	

 	4	 	CITIZENSHIP OR PLACE OF ORGANIZATION	 	
 	 	 	 	 	
 	 	 	 	Delaware	 	
NUMBER OF	 	5	 	SOLE VOTING POWER	 	
SHARES	 	 	 	 	 	
BENEFICIALLY	 	 	 	 	0 shares	 	
OWNED BY	 	6	 	SHARED VOTING POWER	 	
EACH	 	 	 	 	 	
REPORTING	 	 	 	 	2,278,598 (1)	 	
PERSON WITH	 	7	 	SOLE DISPOSITIVE POWER	 	
	 	 	 	 	 	
 	 	 	 	 	0 shares	 	
 	 	8	 	SHARED DISPOSITIVE POWER	 	
 	 	 	 	 	 	
 	 	 	 	 	2,278,598 (1)	 	
 	9	 	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	2,278,598 (1)	 	
 	10	 	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	    ☐	

 	11	 	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	 	
 	 	 	 	 	
 	 	 	 	9.99% (1)	 	
 	12	 	TYPE OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	PN, IA	 	

(1) Includes 992,750 shares of Common Stock currently issuable upon the exercise of the Warrants. Excludes 6,241,535 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock .

6 	
CUSIP No. 925602203

 	1	 	NAME OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	BVF Inc.	 	
 	2	 	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ☒	
 	 	 	 	(b) ☐	
 	 	 	 	 	 	
 	3	 	SEC USE ONLY	 	 	

 	4	 	CITIZENSHIP OR PLACE OF ORGANIZATION	 	
 	 	 	 	 	
 	 	 	 	Delaware	 	
NUMBER OF	 	5	 	SOLE VOTING POWER	 	
SHARES	 	 	 	 	 	
BENEFICIALLY	 	 	 	 	0 shares	 	
OWNED BY	 	6	 	SHARED VOTING POWER	 	
EACH	 	 	 	 	 	
REPORTING	 	 	 	 	2,278,598 (1)	 	
PERSON WITH	 	7	 	SOLE DISPOSITIVE POWER	 	
	 	 	 	 	 	
 	 	 	 	 	0 shares	 	
 	 	8	 	SHARED DISPOSITIVE POWER	 	
 	 	 	 	 	 	
 	 	 	 	 	2,278,598 (1)	 	
 	9	 	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	2,278,598 (1)	 	
 	10	 	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	    ☐	

 	11	 	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	 	
 	 	 	 	 	
 	 	 	 	9.99% (1)	 	
 	12	 	TYPE OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	CO	 	

(1) Includes 992,750 shares of Common Stock currently issuable upon the exercise of the Warrants. Excludes 6,241,535 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock .

7 	
CUSIP No. 925602203

 	1	 	NAME OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	Mark N. Lampert	 	
 	2	 	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ☒	
 	 	 	 	(b) ☐	
 	 	 	 	 	 	
 	3	 	SEC USE ONLY	 	 	

 	4	 	CITIZENSHIP OR PLACE OF ORGANIZATION	 	
 	 	 	 	 	
 	 	 	 	United States	 	
NUMBER OF	 	5	 	SOLE VOTING POWER	 	
SHARES	 	 	 	 	 	
BENEFICIALLY	 	 	 	 	0 shares	 	
OWNED BY	 	6	 	SHARED VOTING POWER	 	
EACH	 	 	 	 	 	
REPORTING	 	 	 	 	2,278,598 (1)	 	
PERSON WITH	 	7	 	SOLE DISPOSITIVE POWER	 	
	 	 	 	 	 	
 	 	 	 	 	0 shares	 	
 	 	8	 	SHARED DISPOSITIVE POWER	 	
 	 	 	 	 	 	
 	 	 	 	 	2,278,598 (1)	 	
 	9	 	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	2,278,598 (1)	 	
 	10	 	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	    ☐	

 	11	 	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	 	
 	 	 	 	 	
 	 	 	 	9.99% (1)	 	
 	12	 	TYPE OF REPORTING PERSON	 	
 	 	 	 	 	
 	 	 	 	IN	 	
  
(1) Includes 992,750 shares of Common Stock currently issuable upon the exercise of the Warrants. Excludes 6,241,535 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock .

8 	
CUSIP No. 925602203

	Item 1(a).	Name of Issuer:	
 
Vical Incorporated, a Delaware corporation (the “Issuer”).
 
	Item 1(b).	Address of Issuer's Principal Executive Offices:	
 
10390 Pacific Center Court
San Diego, California 92121
 
	Item 2(a).	Name of Person Filing	
	Item 2(b).	Address of Principal Business Office or, if None, Residence	
	Item 2(c).	Citizenship	
 
Biotechnology Value Fund, L.P. (“BVF”)
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
 
Biotechnology Value Fund II, L.P. (“BVF2”)
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
 
Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
Citizenship: Cayman Islands
 
BVF Partners OS Ltd. (“Partners OS”)
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
Citizenship: Cayman Islands
 
BVF Partners L.P. (“Partners”)
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
 
BVF Inc.
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
 
Mark N. Lampert (“Mr. Lampert”)
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: United States
 
Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

9 	
CUSIP No. 925602203

	Item 2(d).	Title of Class of Securities:	
 
Common Stock, $0.01 par value (the “Common Stock”).
 
	Item 2(e).	CUSIP Number:	
 
925602203
 
	Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:	
 
 	 	/x/	Not applicable.	
 	 	 	 	
 	(a)	/ /	Broker or dealer registered under Section 15 of the Exchange Act.	
 	 	 	 	
 	(b)	/ /	Bank as defined in Section 3(a)(6) of the Exchange Act.	
 	 	 	 	
 	(c)	/ /	Insurance company as defined in Section 3(a)(19) of the Exchange Act.	
 	 	 	 	
 	(d)	/ /	Investment company registered under Section 8 of the Investment Company Act.	
 	 	 	 	
 	(e)	/ /	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).	
 	 	 	 	
 	(f)	/ /	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).	
 	 	 	 	
 	(g)	/ /	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).	
 	 	 	 	
 	(h)	/ /	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.	
 	 	 	 	
 	(i)	/ /	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.	
 	 	 	 	
 	(j)	/ /	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).  	
 	 	 	 	
 	(k)	/ /	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____	
 
	Item 4.	Ownership	
 
	(a)	Amount beneficially owned:	
 
As of the close of business on December 31, 2018, the Reporting Persons held 7,234,285 warrants, exercisable for an aggregate of 7,234,285 shares of Common Stock (the “Warrants”). Such Warrants have an initial exercise price of $0.01 per share, subject to adjustment pursuant to the terms of the Warrants. The Warrants are only exercisable to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would not beneficially own more than 9.99% of the outstanding Common Stock after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the Warrants (the “Beneficial Ownership Limitation”). As of December 31, 2018, the Beneficial Ownership Limitation limits the aggregate exercise of the Warrants by the Reporting Persons to 992,750 out of the 7,234,285 shares of Common Stock underlying the Warrants owned by the Reporting Persons in the aggregate. In providing beneficial ownership described herein, the Reporting Persons have assumed 992,750 of the 3,590,789 Warrants owned by BVF would be exercised. BVF2 holds Warrants to purchase 2,296,089 additional shares which are excluded herein as a result of the Beneficial Ownership Limitation. BVTOS holds Warrants to purchase 615,779 additional shares which are excluded herein as a result of the Beneficial Ownership Limitation. The Reporting Persons through certain Partners managed accounts (the “Partners Managed Accounts”) holds Warrants to purchase 731,628 additional shares which are excluded herein as a result of the Beneficial Ownership Limitation.

10 	
CUSIP No. 925602203

As of the close of business on December 31, 2018 (i) BVF beneficially owned 1,336,100 shares of Common Stock, including 992,750 shares of Common Stock underlying the Warrants that are currently exercisable, (ii) BVF2 beneficially owned 795,623 shares of Common Stock, and (iii) Trading Fund OS beneficially owned 106,239 shares of Common Stock.
 
Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 106,239 shares of Common Stock beneficially owned by Trading Fund OS.
 
Partners, as the general partner of BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 2,278,598 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, including 40,636 shares of Common Stock held in the Partners Managed Accounts.
 
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 2,278,598 shares of Common Stock beneficially owned by Partners.
 
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 2,278,598 shares of Common Stock beneficially owned by BVF Inc.
 
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
 
	(b)	Percent of class:	
 
The following percentages are based on a denominator which is the sum of: (i) 21,816,041 shares of Common Stock outstanding, which is the total number of share of Common Stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 29, 2018 and (ii) the 992,750 shares of Common Stock underlying certain Warrants, as applicable.
 
As of the close of business on December 31, 2018 (i) BVF beneficially owned approximately 5.9% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 3.7% of the outstanding shares of Common Stock, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding shares of Common Stock, (iv) Partners OS may be deemed to beneficially own less than 1% of the outstanding shares of Common Stock, and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding shares of Common Stock (less than 1% of the outstanding shares of Common Stock is held in the Partners Managed Accounts).

11 	
CUSIP No. 925602203

	(c)	Number of shares as to which such person has:	
 
	(i)	Sole power to vote or to direct the vote	
 
See Cover Pages Items 5-9.
 
	(ii)	Shared power to vote or to direct the vote	
 
See Cover Pages Items 5-9.
 
	(iii)	Sole power to dispose or to direct the disposition of	
 
See Cover Pages Items 5-9.
 
	(iv)	Shared power to dispose or to direct the disposition of	
 
See Cover Pages Items 5-9.
 
	Item 5.	Ownership of Five Percent or Less of a Class.	
 
Not Applicable.
 
	Item 6.	Ownership of More than Five Percent on Behalf of Another Person.	
 
Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts.
 
	Item 7.	Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.	
 
Not Applicable.
 
	Item 8.	Identification and Classification of Members of the Group.	
 
See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on November 17, 2017.
 
	Item 9.	Notice of Dissolution of Group.	
 
Not Applicable.
 
	Item 10.	Certifications.	
 
By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

12 	
CUSIP No. 925602203

SIGNATURE
 
After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
 
Dated: February 1, 2019
 
BIOTECHNOLOGY VALUE FUND, L.P.	 	BVF INC.	
 	 	 		
By:	BVF Partners L.P., its general partner	 	By:	/s/ Mark N. Lampert	
By:	BVF Inc., its general partner	 	 	Mark N. Lampert	
 	 	 	 	President	
By:	/s/ Mark N. Lampert	 	 	 	
 	Mark N. Lampert	 	 	 	
 	President	 	/s/ Mark N. Lampert	
 	 	 	MARK N. LAMPERT	
 	 	 	 	 	
BIOTECHNOLOGY VALUE FUND II, L.P.	 	 	
 	 	 	 	 	
By:	BVF Partners L.P., its general partner	 	 	 	
By:	BVF Inc., its general partner	 	 	 	
 	 	 	 	 	
By:	/s/ Mark N. Lampert	 	 	 	
 	Mark N. Lampert	 	 	 	
 	President	 	 	 	

BVF PARTNERS L.P.	 	 	 	
 	 	 	 	 	
By:	BVF Inc., its general partner	 	 	 	
 	 	 	 	 	
By:	/s/ Mark N. Lampert	 	 	 	
 	Mark N. Lampert	 	 	 	
 	President	 	 	 	

BVF PARTNERS OS LTD.	 	
 	 	 	
By:	BVF Partners L.P., its sole member	 	
By:	BVF Inc., its general partner	 	
 	 	 	
By:	/s/ Mark N. Lampert	 	
 	Mark N. Lampert	 	
 	President	 	

BIOTECHNOLOGY VALUE TRADING FUND OS LP	 	
 	 	 	
By:	BVF Partners L.P., its investment manager	 	
By:	BVF Inc., its general partner	 	
 	 	 	
By:	/s/ Mark N. Lampert	 	
 	Mark N. Lampert	 	
 	President	 	

13